Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Apr;30 Suppl 1(Suppl 1):i67-75.
doi: 10.1093/ndt/gfv008. Epub 2015 Feb 17.

Improved prognosis in Norwegian patients with glomerulonephritis associated with anti-neutrophil cytoplasmic antibodies

Sanjeevan Sriskandarajah  1 , Knut Aasarød  2 , Steinar Skrede  3 , Thomas Knoop  4 , Anna Varberg Reisæter  5 , Rune Bjørneklett  4
Affiliations

Improved prognosis in Norwegian patients with glomerulonephritis associated with anti-neutrophil cytoplasmic antibodies

Sanjeevan Sriskandarajah et al. Nephrol Dial Transplant. 2015 Apr.

Abstract

Background: Glomerulonephritis associated with anti-neutrophil cytoplasmic antibodies (ANCA) is associated with increased mortality and a high risk of end-stage renal disease (ESRD). Here, we investigated whether the prognosis has improved over the last 25 years.

Methods: Patients were identified in the Norwegian Kidney Biopsy Registry. We included all patients with pauci-immune crescentic glomerulonephritis and a positive ANCA test from 1988 to 2012. Deaths and ESRD in the cohort were identified through record linkage with the Norwegian Population Registry (deaths) and the Norwegian Renal Registry (ESRD). Outcomes of patients diagnosed in 1988-2002 were compared with outcomes of patients diagnosed in 2003-12.

Results: A cohort of 455 patients with ANCA-associated glomerulonephritis was identified. The mean follow-up was 6.0 years (range, 0.0-23.4). During the study period, 165 (36%) patients died and 124 (27%) progressed to ESRD. Compared with patients diagnosed in 1988-2002, those diagnosed in 2003-12 had higher mean initial estimated glomerular filtration rates (37 versus 27 mL/min/1.73 m(2)) and lower risk of ESRD (1-year risk: 13 versus 19%; 10-year risk: 26 versus 37%). The composite endpoint, ESRD or death within 0-1 year after diagnosis, was reduced from 34 to 25%. In patients over 60 years old, 1-year mortality fell from 33 to 20%.

Conclusions: In Norwegian patients with ANCA-associated glomerulonephritis, prognosis was significantly better in 2003-12 compared with 1988-2002. This improvement was probably partly due to a shorter diagnostic delay, and better therapeutic management in older patients.

Keywords: ANCA-associated glomerulonephritis; diagnostic delay; end-stage renal disease; mortality; prognosis.

PubMed Disclaimer

Figures

FIGURE 1:
FIGURE 1:
Flow chart shows the outcomes of 455 patients with AAGN in the study cohort. (A) All patients in the TFU period. (B) Patients included in the short follow-up period. (C) Patients included in the long follow-up period. AAGN, anti-neutrophil cytoplasmic antibody-associated glomerulonephritis; ESRD, end-stage renal disease.
FIGURE 2:
FIGURE 2:
Kaplan–Meier plots show renal survival in 455 patients with AAGN stratified by early (1988–2002) and late (2003–12) study periods. (A) All patients. (B) Patients aged <60 years. (C) Patients aged ≥60 years. AAGN, anti-neutrophil cytoplasmic antibodies associated glomerulonephritis; ESRD, end-stage renal disease.
FIGURE 3:
FIGURE 3:
Kaplan–Meier plots show 1-year survival in 455 patients with AAGN stratified by study period (1988–2002 versus 2003–12). (A) All patients. (B) Patients aged <60 years. (C) Patients aged ≥60 years. AAGN, anti-neutrophil cytoplasmic antibodies associated glomerulonephritis; ESRD, end-stage renal disease.
FIGURE 4:
FIGURE 4:
Kaplan–Meier plots show 1-year risk of ESRD or death in 455 patients with AAGN stratified by study period (1988–2002 versus 2003–12). (A) All patients. (B) Patients aged <60 years. (C) Patients aged 60–74.9 years. (D) Patients aged ≥75 years. AAGN, anti-neutrophil cytoplasmic antibodies associated glomerulonephritis; ESRD, end-stage renal disease.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Couser WG. Rapidly progressive glomerulonephritis: classification, pathogenetic mechanisms, and therapy. Am J Kidney Dis 1988; 11: 449–464 - PubMed
    1. Falk RJ, Jennette JC. ANCA disease: where is this field heading? J Am Soc Nephrol 2010; 21: 745–752 - PubMed
    1. Walton EW. Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis). Br Med J 1958; 2: 265–270 - PMC - PubMed
    1. Aasarod K, Iversen BM, Hammerstrom J, et al. Wegener's granulomatosis: clinical course in 108 patients with renal involvement. Nephrol Dial Transplant 2000; 15: 2069. - PubMed
    1. Heijl C, Harper L, Flossmann O, et al. Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials. Ann Rheum Dis 2011; 70: 1415–1421 - PubMed

Substances